Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

About

About ATTR-CM

MOD/MOA

Study Design

Menu

Close

Access & Support

Access & Patient Support

Events

Materials

Videos

  • Prescribing Information
  • Patient Information
  • Patient Site

  • Access & Patient Support

    Patient access and reimbursement

    Financial assistance options

    Additional support during treatment

    When you've decided VYNDAMAX® (tafamidis) is appropriate for your patient, VyndaLink can help*

    Enroll your patients in VyndaLink for support

    The VyndaLink team can:​​​​​​​

    Conduct a benefits verification to determine your patient's coverage for VYNDAMAX, including out-of-pocket costs

    Determine payer requirements and provide information about the prior authorization process and appeals process as needed

    Identify Specialty Pharmacy options based on your patient’s insurance coverage. VYNDAMAX is available through multiple Specialty Pharmacies in our defined distribution network

      *The same VyndaLink support offerings available to patients prescribed VYNDAMAX are also available to patients prescribed VYNDAQEL (tafamidis meglumine).

       †Please note where a PA is required, the physician must submit required information directly to the patient's insurer.

    Get started at www.VyndaLink.com

    Download the enrollment form and fax completed forms to 1-888-878-8474. You can also complete the enrollment form online at www.VyndaLinkPortal.com. Call VyndaLink at 1-888-222-8475 (Monday-Friday, 8 AM-8 PM ET) with any questions.

    Visit VyndaLink

    Next: Financial assistance options

    The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.

    Continue

    ** This is an optional area where footnotes can live.

    Access & Support

    Access & Patient Support
    • Events
    • Materials
    • Videos

    VyndaLink.com has more information about support services for you and your patients

    View VyndaLink

    Access resources for you and your patient

    Explore resources


    VYNDAMAX® AND VYNDAQEL® are registered trademarks of Pfizer Inc.

    Adverse Reactions

    In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

    Specific Populations

    Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

    Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

    VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
    ​​​​​​​
    Please see Full Prescribing Information including Patient Information.

      INDICATION AND LIMITATIONS OF USE

      VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
      ​​​​​​​
      Please see Full Prescribing Information including Patient Information.

              Please see full Prescribing Information.

              OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative.

              If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window. ​​​​​​​

              Would you like to sign in now? ​​​​​​​